Vitamin K2 (menaquinone) has shown promising effects on diabetes in animal models. Does it hold up in humans?

The study

In this 12-week randomized controlled trial, 45 patients with type 2 diabetes took either 200 μg of vitamin K2 or a placebo. Markers of cardiovascular and metabolic health such as blood pressure, HbA1c, and blood lipids were measured at baseline and 12 weeks.

The results

The intervention group had reduced HbA1c, fasting blood glucose, fasting insulin, and insulin resistance. Other markers did not change.

Every month we summarize over 150 of the most noteworthy health and nutrition studies. Other health categories related to this summary include:Try Examine+ for free to view the latest research in 25 health categories and the entire Study Summaries archive, access our Supplement Guides, and unlock the Examine Database. Plus, earn continuing education credits!

Get free weekly updates on what’s new at Examine.

This Study Summary was published on September 4, 2020.